Edition:
United States

Pharming Group NV (PHGUF.PK)

PHGUF.PK on OTC Markets Group - US Other OTC and Grey Market

0.96USD
16 Oct 2017
Change (% chg)

$-0.02 (-1.95%)
Prev Close
$0.98
Open
$0.96
Day's High
$0.96
Day's Low
$0.96
Volume
39,000
Avg. Vol
194,645
52-wk High
$0.98
52-wk Low
$0.22

Latest Key Developments (Source: Significant Developments)

Pharming Group partners with Inceptua Medicines Access
Tuesday, 26 Sep 2017 01:00am EDT 

Sept 26 (Reuters) - PHARMING GROUP NV ::PHARMING GROUP N.V. AND HAEI INTERNATIONAL PATIENT ORGANIZATION ANNOUNCE PARTNERSHIP WITH INCEPTUA MEDICINES ACCESS FOR "HAEI GLOBAL ACCESS PROGRAM".‍APPOINTMENT OF INCEPTUA MEDICINES ACCESS AS THEIR NEW DISTRIBUTION PARTNER FOR "HAEI GLOBAL ACCESS PROGRAM"​.  Full Article

Pharming Group announces cashless warrant exercises and conversions of its ordinary bonds into shares
Thursday, 10 Aug 2017 01:01am EDT 

Aug 10 (Reuters) - PHARMING GROUP NV ::ANNOUNCES CASHLESS WARRANT EXERCISES AND CONVERSIONS OF ITS ORDINARY BONDS INTO SHARES.AS RESULT OF THESE CONVERSIONS, TOTAL AMOUNT OUTSTANDING OF ORDINARY BONDS HAS BEEN REDUCED FROM EUR 11.8 MILLION TO EUR 11.6 MILLION.15,587,579 SHARES RECOVERED THROUGH CASHLESS EXERCISE REPRESENT 3% OF ISSUED SHARE CAPITAL, AND THEREFORE 3% LOWER DILUTION OF SHAREHOLDERS IN FUTURE.REMAINING SHARES REPRESENTED BY OUTSTANDING WARRANTS NOW REDUCED TO 50,470,886, WHICH REPRESENTS LESS THAN 10% OF OUTSTANDING SHARES.NUMBER OF WARRANTS EXERCISABLE HAS BEEN REDUCED BY 27,042,254 IN TOTAL DUE TO CASHLESS EXERCISES.NET RESULT IS A REDUCTION OF FULLY DILUTED SHARE CAPITAL.  Full Article

Pharming Group H1 net loss widens to 30.2 million euros
Thursday, 27 Jul 2017 01:00am EDT 

July 27 (Reuters) - PHARMING GROUP NV ::SAID ON THURSDAY THAT REVENUES FROM PRODUCT SALES FOR THE HALF YEAR INCREASED BY 617 PCT TO EUR 30.1 MILLION (HY 2016: EUR 4.2 MILLION).H1 TOTAL REVENUES INCREASED BY 477 PCT TO EUR 30.6 MILLION (INCLUDING EUR 0.5 MILLION OF LICENSE REVENUE) FROM EUR 5.3 MILLION (INCLUDING EUR 1.1 MILLION IN LICENSE REVENUE) IN HY 2016.H1 OPERATING RESULTS IMPROVED TO A PROFIT OF EUR 4.2 MILLION FROM A LOSS OF EUR 6.2 MILLION IN HY 2016, DESPITE A CONSIDERABLE INCREASE IN COMMERCIALIZATION ACTIVITIES, ESPECIALLY IN THE US.H1 NET RESULT WAS A LOSS OF EUR 30.2 MILLION (HY 2016: LOSS OF EUR 6.7 MILLION).COMPANY’S CASH POSITION DECREASED FROM EUR 32.1 MILLION AT YEAR-END 2016 TO EUR 25.2 MILLION AT 30 JUNE 2017 (UP FROM EUR 21.7 MILLION AT 30 JUNE 2016).CONTINUES TO EXPECT ADDITIONAL POSITIVE OPERATING RESULTS FOR THE REMAINDER OF THE YEAR.  Full Article

Pharming withdraws items related to amendment of articles of association from AGM agenda
Wednesday, 17 May 2017 07:30am EDT 

May 17 (Reuters) - PHARMING GROUP NV ::PHARMING ANNOUNCES WITHDRAWAL OF AGENDA ITEMS RELATED TO AMENDMENT OF THE ARTICLES OF ASSOCIATION FROM AGM AGENDA.  Full Article

Pharming Group Q1 operating result swings to EUR 3.9 mln profit
Wednesday, 17 May 2017 01:00am EDT 

May 17 (Reuters) - PHARMING GROUP NV :Q1 NET PRODUCT SALES INCREASED BY 794% TO €15.2 MILLION (2016: €1.7 MILLION),.Q1 TOTAL REVENUES INCREASED BY 605% TO €15.5 MILLION FROM €2.2 MILLION IN 2016.Q1 OPERATING RESULTS IMPROVED TO A PROFIT OF €3.9 MILLION FROM A LOSS OF €3.2 MILLION IN 2016.Q1 NET RESULT WAS A LOSS OF €5.7 MILLION, COMPARED WITH A LOSS OF €3.4 MILLION IN 2016.  Full Article

Pharming announces refinancing of its existing debt by single $100 million debt facility on improved commercial terms
Tuesday, 16 May 2017 01:00am EDT 

May 16 (Reuters) - PHARMING GROUP NV ::PHARMING ANNOUNCES REFINANCING OF ITS EXISTING DEBT BY A SINGLE US$100 MILLION DEBT FACILITY ON IMPROVED COMMERCIAL TERMS.REPAYMENT OF AMORTISING CONVERTIBLE BONDS ELIMINATES RISK OF APPROXIMATELY 24% DILUTION.IT HAS COMPLETED A NEW US$100 MILLION FINANCE AGREEMENT WITH ORBIMED ADVISORS.THIS HAS BEEN USED TO REDEEM AMORTIZING CONVERTIBLE BONDS DUE 2017/2018, AND TO REFINANCE COMPANY'S SENIOR DEBT FACILITY WITH SILICON VALLEY BANK AND KREOS CAPITAL.LOAN, INITIALLY STRUCTURED AS A BRIDGE FACILITY WILL BE REPLACED WITHIN 60 DAYS BY A FULL LOAN AGREEMENT WITH A MATURITY DATE OF JUNE 2021.SIGNIFICANT REDUCTION OF NEAR TERM CASH BURN (FROM AMORTISATIONS AND DEBT REPAYMENTS) OF APPROXIMATELY EUR 16 MILLION IN 2017 AND ALMOST EUR 8 MILLION IN 2018.  Full Article

Pharming Group FY net loss widens to 17.5 million euros
Thursday, 9 Mar 2017 01:00am EST 

Pharming Group NV : FY revenue from product sales 13.7 million euros ($14.43 million) versus 8.6 million euros year ago . FY revenue 15.9 million euros versus 10.8 million euros year ago . FY net loss 17.5 million euros versus loss of 10.0 million euros year ago . Cash position, including restricted cash, 32.1 million euros at year-end 2016 versus 31.8 million euros at year-end 2015 . For 2017 sees continued growth in revenues from sales of RUCONEST, mainly driven by the US operations .For 2017 sees achievement of positive quarterly operating results in the course of the year.  Full Article

Pharming Group announces additional conversions of its amortizing bonds
Friday, 3 Feb 2017 01:00am EST 

Pharming Group NV : Announces additional conversions of its amortizing bonds . Total number of shares issued in conversions is 7,558,479 ordinary shares . Amount of amortizing bonds outstanding is reduced from 45.0 million euros ($48.4 million) to 39.7 million euros .No cash payment was required in respect of first instalment of bonds due on Feb 1, 2017 and second installment due on March 1, 2017 has now also been mostly settled.  Full Article

Pharming Group announces issue of new stock
Thursday, 26 Jan 2017 03:23am EST 

Pharming Group NV : Announces issue of new stock as a result of conversion of amortizing bonds . Total number of shares issued in conversions is 10,823,881 ordinary shares . Amount of amortizing bonds outstanding is reduced from 45.0 million euros ($48.32 million) to 41.9 million euros .New shares represent 2.38 pct of issued share capital of company prior to issue, and 2.32 pct of enlarged issued share capital of company.  Full Article

EC amends marketing authorisation for Pharming Group's Ruconest to include self-administration
Monday, 16 Jan 2017 04:02am EST 

Pharming Group NV : European Commission amends marketing authorisation for Ruconest to include self-administration . European Commission adopted Commission Implementing Decision to amend marketing authorisation for Ruconest to include self administration using Ruconest Administration Kit . Decision allows for self-administration of Ruconest for acute hereditary angioedema (HAE) attacks by adolescents and adults with a new custom-designed Ruconest Administration Kit .Ruconest Administration Kit will become available for use in various EU markets, following approval of educational materials by local authorities, expected over coming 1-3 mths.  Full Article